Poor outcome in post transplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years' experience in a single institute
about
Clinical characteristics of monomorphic post-transplant lymphoproliferative disordersDonor-derived second hematologic malignancies after cord blood transplantation.An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome.Is there a difference in post-transplant lymphoproliferative disorder in adults after solid organ and haematologic stem cell transplantation? Experience in 41 patients.Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation.High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts.EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT.Very late relapse of PTLD 10 yr after allogeneic HSCT and nine yr after stopping immunosuppressive therapy.Phase-1 study of siplizumab in the treatment of pediatric patients with at least grade II newly diagnosed acute graft-versus-host disease.Endobronchial Epstein-Barr Virus Associated Post-transplant Lymphoproliferative Disorder in Hematopoietic Stem Cell Transplantation.Epstein-Barr virus (EBV) load in cerebrospinal fluid and peripheral blood of patients with EBV-associated central nervous system diseases after allogeneic hematopoietic stem cell transplantation.Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation.Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation.Respiratory failure in the hematopoietic stem cell transplant recipient
P2860
Q33749906-761F0378-67CC-4200-8BE2-FE5026D9BF94Q33952705-39879E51-4D71-4752-8900-789D51A80C5EQ35694784-96767E6A-078F-4591-8E38-41D7E2273F64Q36295658-5F2D4DB0-A6B7-4C98-B72A-C69BB21D6FDEQ37012569-AA825A3A-4DF2-4F0D-A7BF-9CBD1469C8C0Q37807871-5DDB6574-A7B0-40C5-A49D-02D9C8D8F95CQ38119843-C01B82E7-8B03-4266-84AE-03344397B489Q40230220-214699F4-870B-4EA0-B0C5-F2C7D35AC717Q40382580-D28FCFA5-D702-429F-A245-89C5F2ABEB7CQ41908744-DC9F2F2C-2220-4634-9A6E-83DCC6FF2B72Q45351139-4E46A44E-8343-41A8-90C2-1732C541B892Q45351795-6599CB15-2BA5-43DC-9C86-7C9BE0FBAACCQ45363416-60975540-941F-406C-950B-FE3BF55DAD91Q58121933-FEA60C2E-0687-4946-89FB-C409C584EDD8
P2860
Poor outcome in post transplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years' experience in a single institute
description
im Oktober 2008 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 06 October 2008
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в жовтні 2008
@uk
name
Poor outcome in post transplan ...... perience in a single institute
@en
Poor outcome in post transplan ...... perience in a single institute
@nl
type
label
Poor outcome in post transplan ...... perience in a single institute
@en
Poor outcome in post transplan ...... perience in a single institute
@nl
prefLabel
Poor outcome in post transplan ...... perience in a single institute
@en
Poor outcome in post transplan ...... perience in a single institute
@nl
P2093
P2860
P50
P356
P1476
Poor outcome in post transplan ...... perience in a single institute
@en
P2093
P2860
P2888
P304
P356
10.1038/BMT.2008.325
P407
P577
2008-10-06T00:00:00Z